Our Products

Regensight holds in its capacity a CEI EN ISO 13485:2021 quality management system for design, manufacturing management and marketing of ophthalmic active medical devices and related sterile accessories. The notified body is TÜV Rheinland Italia.

C4V CHROMO4VIS®

UV-A medical device with exponential and key-enabling technologies

RitSight®

 0.22% riboflavin ophthalmic solution for corneal cross-linking

DoRSight®

 Corneal iontophoresis controlled delivey system.
For exclusive use with C4V CHROMO4VIS®

For professionals

To medical professionals

At the heart of our startup is the belief that revolutionary, life-changing, treatments of visual disorders needs courageous science and surgeon oriented perspective to deliver effective and safe outcomes to patients.In order to achieve the greatest benefit, our goal is to be representative of the eye surgeons’ needs to improve their patients’ care.

Know more on theranostic UV C4V CHROMO4VIS® device: FAQ


Do you want a product demonstration?
Contact us at customers@regensight.com

Do you have a project idea?
Contact us at 4social@regensight.com

For patient advocacy groups

Our startup strives to collaborate with patient advocacy groups understanding patients’ experiences, opinions and concerns in order to embed these perspectives into our decisions for the clinical development of products that truly know how to solve the unmet needs of patients.
Our goal is to design therapies and clinical trials that are representative of the communities we serve.
We deeply value the partnerships and collaborations.
Contact us at 4social@regensight.com

FAQ

Theranostics represents a quantum leap in precision medicine for the cornea, improving the efficacy and safety of treatments with a targeted and evidence-based approach in real time. 

The use of C4V CHROMO4VIS® offers several significant clinical benefits for treatment of keratoconus and corneal pathologies:

  1. Personalized Treatment: it allows to adapt each treatment according to the ultrastructural, biomechanical and optical properties of the cornea of the individual patient, improving the efficacy of the procedure.
  2. Objective Monitoring: its ability to measure and verify in real time the concentration of riboflavin in the cornea and the treatment effect, improves the reliability and safety of the procedure, drastically reducing the variability of clinical outcomes.
  3. Increased Accuracy: real-time monitoring of the application of riboflavin in the cornea and its UV-A light mediated photo-activation allows to optimize the therapeutic effect and reduce the risk of adverse events to the corneal tissue of each patient.
  4. Innovation in Treatments: the exponential technologies integrated into the C4V CHROMO4VIS® theranostic device are paving the way for new approaches for treatments with predictive personalization of the therapeutic benefit, with increasingly advanced potential applications.

C4V CHROMO4VIS’s theranostics learning curve is relatively quick both for the surgeon, who has experience with traditional corneal cross-linking and for young surgeons, thanks to the intuitive graphical interface and the real-time guidance offered by the system.

The full adoption of the technology and the optimization of clinical use to take full advantage of its potential depend on a few key factors:

  1. Initial Training: learning the functionality of the device, including the interpretation of theranostic imaging biomarkers, requires a short initial training phase.
  2. Continuous Use: after the first few procedures, the surgeon becomes progressively more confident in interpreting data in real time and applying personalized protocols.
  3. Integration into Clinical Flows: the inclusion of technology in daily practice requires a short period of adaptation to optimize time and operating methods.
  4. Refinement of the Therapeutic Strategy: with experience, the ability to adapt treatment parameters, such as the amount of riboflavin and UV irradiation and light energy, is improved, maximizing the effectiveness of the results for each patient.

In conclusion, after just a few procedures, the surgeon can handle the theranostic treatment with confidence. After a few dozen treatments, the surgeon has full mastery of the technology and the use of theranostics becomes highly personalized and efficient.

C4V CHROMO4VIS® theranostics improves the care of your patients through more precise, personalized and predictive treatment of the therapeutic benefit for keratoconus and other corneal diseases. Key benefits of C4V CHROMO4VIS® include:

  1. Personalized treatment

The theranostic device analyzes the amount of riboflavin applied in the cornea in real time and assures the surgeon that each cornea receives the right dose of vitamin B2, based on its specific characteristics, before UV-A light phototherapy.

This approach minimizes uncertainty in outcomes and maximizes treatment efficacy.

  1. Increased Security and Control

Real-time measurement of treatment parameters ensures the highest level of safety, avoiding over- or under-treatment, minimizing risks for the patient.

  1. Reduction of Clinical Variability

The use of objective parameters allows for more predictable and reproducible results, reducing the variability of clinical outcomes between patients.

  1. Better visual results

Compared to standard corneal cross-linking, theranostics reduces corneal optical aberrations, improving the patient’s visual quality.

Partnering

Regensight is establishing its global presence through selected authorized distibutors. marketing our high-technological medical products via out-licensing.
We are looking for partners in global markets providing high standards of service in the eye surgical sector to distribute our proprietary patented technology to serve world population.

If interested in our breakthrough product portfolio, please contact us at partnering@regensight.com, attaching a company curriculum and indicating your Territory of interest. Our Team will back to you soon.

 

Associations

Regensight is associated with Confindustria Medical Devices and Innovup.